Subscribe to 51精品视频wire Today
Get the most interesting and important stories from the 51精品视频.Technologies developed in 51精品视频's McGowan Lab were licensed for development
ECM Therapeutics has licensed multiple extracellular matrix (ECM) technologies developed in the laboratory of Stephen Badylak at the , including hydrogels, bioactive derivatives and methods for delivering these materials within the body.聽
The聽51精品视频sburgh based company will initially develop EsophaGel, an ECM hydrogel for the treatment of Barrett's Esophagus which is often a precursor to esophageal cancer. EsophaGel has been shown in preclinical studies to halt and possibly reverse the progression of esophageal cancer.聽聽
鈥淲e are pleased to license this portfolio of patents and patent applications to a startup company based in the聽51精品视频sburgh聽region,鈥 said聽Alex Ducruet, director for licensing and intellectual property in聽51精品视频's聽. 鈥淒r. Badylak is one of聽51精品视频's聽most prolific innovators, and we look forward to the positive impact that these regenerative medicine technologies will have on people's lives.鈥
ECM Therapeutics was founded by Badylak and business development colleague聽Katie Collins. Badylak lab members Jenna Dziki聽and聽George Hussey and the 51精品视频 hold equity in the company.